#United States #Clinical Research #Raleigh, North Carolina #ProPharma #Dan Ryan

ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions

ProPharma, a recognized leader in providing regulatory, clinical, and compliance services for the life sciences industry, recently announced the appointment of Dan Ryan as the new President of its Clinical Research Solutions (CRS) division. This strategic move is set to bolster ProPharma's position in the market, where operational excellence and scientific rigor are increasingly pivotal.

Dan Ryan joins ProPharma with nearly 20 years of extensive experience in clinical trial management across biotechnology and Contract Research Organizations. His previous significant role as the Vice President and Global Hematology and Oncology Therapeutic Head at ICON depicts his proficiency in the domain. His career also includes notable positions at G1 Therapeutics, Worldwide Clinical Trials, and Syneos Health. Dan’s background encompasses a comprehensive understanding of clinical trial processes, international regulations, and an in-depth experience managing phases I-III clinical trials, which include complex protocol designs.

In his new role, Dan will take the reins of ProPharma's full-service clinical trials service line. His insights and leadership will be instrumental in navigating the complexities of the clinical landscape, ensuring that ProPharma delivers the needed services efficiently to sponsors and partners involved in advancing clinical research. Dan expressed enthusiasm about joining the ProPharma team, emphasizing the organization's unique position to meet the intricate demands of today's clinical environments. He remarked, “I’m honored to join this exceptional team as we continue strengthening our full-service capabilities and accelerating the delivery of life-changing therapies to patients worldwide.”

Moreover, ProPharma has recently augmented its operations by launching the Functional Service Provider (FSP) Solutions. This new focus area builds on the success of its longstanding FSP services and aims to offer comprehensive support extending to Regulatory Affairs, Pharmacovigilance, and Quality Assurance. Kevin Wysocki, who has been appointed as the President of FSP Solutions, will lead this endeavor.

Jason DeGoes, President of ProPharma, highlighted the significance of this transition in their Clinical Commercial structure, which aims at ensuring seamless and effective trials through scalable research solutions supported by decades of hierarchy and expertise. “Dan's expertise is a perfect complement to Kevin's as we strive to exceed market demands. We’re excited to have him on board and working with Kevin to effectively manage current and expected growth across both CRS and FSP,” he added.

With over 25 years of continuous service in the life sciences sector, ProPharma is committed to enhancing patient health and wellness through its wide range of consulting solutions. Their expertise spans regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, and digital transformation - all contributing to the success of biotech, medical device, and pharmaceutical firms of varying sizes strive to introduce groundbreaking therapies.

The announcement comes at a critical time as healthcare organizations globally are adapting to new challenges. As ProPharma positions itself to address these challenges, the focus on executive leadership through appointments like Dan Ryan reinforces its commitment to providing top-tier clinical services.

For more information about ProPharma and its various offerings, be sure to visit their website at propharmagroup.com.

About ProPharma

ProPharma specializes in empowering enterprises through expertise that enables confidence in clinical trials, regulatory compliance, and advancing scientific breakthroughs - all while minimizing risks in high-profile drug and medical device programs.

About Odyssey Investment Partners

Odyssey Investment Partners is a private equity investment firm with a prominent history, focusing on elevating middle-market companies into productive and diversified entities with substantial growth possibilities.